{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T11:50:42Z","timestamp":1793274642147,"version":"4.5.0"},"reference-count":65,"publisher":"Impact Journals, LLC","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2023,4,14]]},"DOI":"10.18632\/oncotarget.28410","type":"journal-article","created":{"date-parts":[[2023,4,14]],"date-time":"2023-04-14T08:30:22Z","timestamp":1681461022000},"page":"342-350","source":"Crossref","is-referenced-by-count":69,"title":["Cancer prevention with rapamycin"],"prefix":"10.18632","volume":"14","author":[{"given":"Mikhail V.","family":"Blagosklonny","sequence":"first","affiliation":[{"name":"Roswell Park Comprehensive Cancer Center, Buffalo, NY 14263, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"7892","published-online":{"date-parts":[[2023,4,14]]},"reference":[{"key":"1","doi-asserted-by":"publisher","first-page":"2281","DOI":"10.1158\/1078-0432.CCR-06-2570","article-title":"Identification of a highly effective rapamycin schedule that markedly reduces the size, multiplicity, and phenotypic progression of tobacco carcinogen-induced murine lung tumors","volume":"1","author":"Dennis","year":"2007","journal-title":"Clin Cancer Res"},{"key":"2","doi-asserted-by":"publisher","first-page":"2925","DOI":"10.3892\/or.2015.4277","article-title":"Early and delayed intervention with rapamycin prevents NNK-induced lung adenocarcinoma in A\/J mice","volume":"3","author":"Rao","year":"2015","journal-title":"Oncol Rep"},{"key":"3","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1593\/neo.05652","article-title":"Efficacy of polyphenon E, red ginseng, and rapamycin on benzo(a)pyrene-induced lung tumorigenesis in A\/J mice","volume":"8","author":"You","year":"2006","journal-title":"Neoplasia"},{"key":"4","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1016\/j.celrep.2014.05.039","article-title":"Rapamycin prevents the development and progression of mutant epidermal growth factor receptor lung tumors with the acquired resistance mutation T790M","volume":"7","author":"Dennis","year":"2014","journal-title":"Cell Rep"},{"key":"5","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1158\/1940-6207.CAPR-08-0147","article-title":"Targeting mammalian target of rapamycin by rapamycin prevents tumor progression in an oral-specific chemical carcinogenesis model","volume":"2","author":"Gutkind","year":"2009","journal-title":"Cancer Prev Res (Phila)"},{"key":"6","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1158\/1940-6207.CAPR-08-0215","article-title":"Rapamycin for chemoprevention of upper aerodigestive tract cancers","volume":"2","author":"Dennis","year":"2009","journal-title":"Cancer Prev Res (Phila)"},{"key":"7","doi-asserted-by":"publisher","first-page":"2092","DOI":"10.2353\/ajpath.2010.091050","article-title":"Rapamycin extends maximal lifespan in cancer-prone mice","volume":"17","author":"Blagosklonny","year":"2010","journal-title":"Am J Pathol"},{"key":"8","doi-asserted-by":"publisher","first-page":"586","DOI":"10.4161\/cbt.28164","article-title":"Lifespan extension and cancer prevention in HER-2\/neu transgenic mice treated with low intermittent doses of rapamycin","volume":"1","author":"Blagosklonny","year":"2014","journal-title":"Cancer Biol Ther"},{"key":"9","doi-asserted-by":"publisher","first-page":"715","DOI":"10.18632\/aging.100496","article-title":"New nanoformulation of rapamycin Rapatar extends lifespan in homozygous p53\u2212\/\u2212 mice by delaying carcinogenesis","volume":"4","author":"Antoch","year":"2012","journal-title":"Aging (Albany NY)"},{"key":"10","doi-asserted-by":"publisher","first-page":"709","DOI":"10.18632\/aging.100498","article-title":"Rapamycin extends lifespan and delays tumorigenesis in heterozygous p53+\/\u2212 mice","volume":"4","author":"Gudkov","year":"2012","journal-title":"Aging (Albany NY)"},{"key":"11","doi-asserted-by":"publisher","first-page":"100","DOI":"10.18632\/aging.100533","article-title":"Rapamycin extends life span of Rb1+\/\u2212 mice by inhibiting neuroendocrine tumors","volume":"5","author":"Sharp","year":"2013","journal-title":"Aging (Albany NY)"},{"key":"12","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1002\/path.6009","article-title":"Long-term treatment of cancer-prone germline PTEN mutant mice with low-dose rapamycin extends lifespan and delays tumour development","volume":"25","author":"Vanhaesebroeck","year":"2022","journal-title":"J Pathol"},{"key":"13","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.18632\/oncotarget.27550","article-title":"Superior cancer preventive efficacy of low versus high dose of mTOR inhibitor in a mouse model of prostate cancer","volume":"1","author":"Gudkov","year":"2020","journal-title":"Oncotarget"},{"key":"14","doi-asserted-by":"publisher","first-page":"5304","DOI":"10.1158\/1078-0432.CCR-12-1371","article-title":"Chemopreventive and chemotherapeutic actions of mTOR inhibitor in genetically defined head and neck squamous cell carcinoma mouse model","volume":"1","author":"Kulkarni","year":"2012","journal-title":"Clin Cancer Res"},{"key":"15","doi-asserted-by":"publisher","first-page":"13544","DOI":"10.1073\/pnas.0800041105","article-title":"Inhibition of the mTORC1 pathway suppresses intestinal polyp formation and reduces mortality in ApcDelta716 mice","volume":"10","author":"Taketo","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"16","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1038\/onc.2009.435","article-title":"Rapamycin inhibits oncogenic intestinal ion channels and neoplasia in APC(Min\/+) mice","volume":"2","author":"Kunzelmann","year":"2010","journal-title":"Oncogene"},{"key":"17","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1158\/1940-6207.CAPR-13-0299","article-title":"eRapa restores a normal life span in a FAP mouse model","volume":"7","author":"Sharp","year":"2014","journal-title":"Cancer Prev Res (Phila)"},{"key":"18","doi-asserted-by":"publisher","first-page":"e61","DOI":"10.1016\/j.clcc.2020.08.006","article-title":"Rapamycin Extends Life Span in Apc(Min\/+) Colon Cancer FAP Model","volume":"2","author":"Sharp","year":"2021","journal-title":"Clin Colorectal Cancer"},{"key":"19","doi-asserted-by":"publisher","first-page":"2408","DOI":"10.1158\/0008-5472.CAN-06-4490","article-title":"RAD001 (Everolimus) delays tumor onset and progression in a transgenic mouse model of ovarian cancer","volume":"6","author":"Testa","year":"2007","journal-title":"Cancer Res"},{"key":"20","doi-asserted-by":"publisher","first-page":"8140","DOI":"10.18632\/aging.204354","article-title":"Rapamycin treatment early in life reprograms aging: hyperfunction theory and clinical practice","volume":"1","author":"Blagosklonny","year":"2022","journal-title":"Aging (Albany NY)"},{"key":"21","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1038\/nature08221","article-title":"Rapamycin fed late in life extends lifespan in genetically heterogeneous mice","volume":"46","author":"Miller","year":"2009","journal-title":"Nature"},{"key":"22","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1093\/gerona\/glq178","article-title":"Rapamycin, but not resveratrol or simvastatin, extends life span of genetically heterogeneous mice","volume":"6","author":"Sharp","year":"2011","journal-title":"J Gerontol A Biol Sci Med Sci"},{"key":"23","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1111\/j.1474-9726.2012.00832.x","article-title":"Rapamycin slows aging in mice","volume":"1","author":"Miller","year":"2012","journal-title":"Aging Cell"},{"key":"24","doi-asserted-by":"publisher","first-page":"4230","DOI":"10.4161\/cc.10.24.18486","article-title":"Rapamycin increases lifespan and inhibits spontaneous tumorigenesis in inbred female mice","volume":"1","author":"Blagosklonny","year":"2011","journal-title":"Cell Cycle"},{"key":"25","doi-asserted-by":"publisher","first-page":"3272","DOI":"10.1172\/JCI67674","article-title":"Rapamycin extends murine lifespan but has limited effects on aging","volume":"12","author":"Holtmeier","year":"2013","journal-title":"J Clin Invest"},{"key":"26","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1111\/j.1399-0012.2004.00188.x","article-title":"Two-year incidence of malignancy in sirolimus-treated renal transplant recipients: results from five multicenter studies","volume":"1","author":"Friend","year":"2004","journal-title":"Clin Transplant"},{"key":"27","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1097\/01.tp.0000184006.43152.8d","article-title":"Maintenance immunosuppression with target-of-rapamycin inhibitors is associated with a reduced incidence of de novo malignancies","volume":"8","author":"Kahan","year":"2005","journal-title":"Transplantation"},{"key":"28","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1681\/ASN.2005090993","article-title":"Sirolimus therapy after early cyclosporine withdrawal reduces the risk for cancer in adult renal transplantation","volume":"1","author":"Brault","year":"2006","journal-title":"J Am Soc Nephrol"},{"key":"29","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1056\/NEJMoa1204166","article-title":"Sirolimus and secondary skin-cancer prevention in kidney transplantation","volume":"36","author":"Hofbauer","year":"2012","journal-title":"N Engl J Med"},{"key":"30","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1016\/j.ejca.2012.09.013","article-title":"Risk of de novo cancers after transplantation: results from a cohort of 7217 kidney transplant recipients, Italy 1997-2009","volume":"4","author":"Tisone","year":"2013","journal-title":"Eur J Cancer"},{"key":"31","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1093\/ndt\/gfw088","article-title":"Immunosuppression with mammalian target of rapamycin inhibitor and incidence of post-transplant cancer in kidney transplant recipients","volume":"3","author":"D\u00f6hler","year":"2016","journal-title":"Nephrol Dial Transplant"},{"key":"32","doi-asserted-by":"publisher","first-page":"2612","DOI":"10.1200\/JCO.2017.76.6691","article-title":"Sirolimus for Secondary Prevention of Skin Cancer in Kidney Transplant Recipients: 5-Year Results","volume":"3","author":"Hofbauer","year":"2018","journal-title":"J Clin Oncol"},{"key":"33","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1080\/0886022X.2020.1785499","article-title":"The impact of switching to mTOR inhibitor-based immunosuppression on long-term non-melanoma skin cancer incidence and renal function in kidney and liver transplant recipients","volume":"4","author":"Ni Raghallaigh","year":"2020","journal-title":"Ren Fail"},{"key":"34","doi-asserted-by":"publisher","first-page":"322","DOI":"10.3390\/jcm11020322","article-title":"Sirolimus-Based Immunosuppression Is Associated with Decreased Incidence of Post-Transplant Lymphoproliferative Disorder after Heart Transplantation: A Double-Center Study","volume":"1","author":"Kushwaha","year":"2022","journal-title":"J Clin Med"},{"key":"35","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1634\/theoncologist.2009-0178","article-title":"FDA approval summary: temsirolimus as treatment for advanced renal cell carcinoma","volume":"1","author":"Pazdur","year":"2010","journal-title":"Oncologist"},{"key":"36","doi-asserted-by":"publisher","first-page":"2271","DOI":"10.1056\/NEJMoa066838","article-title":"Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma","volume":"35","author":"Schmidt-Wolf","year":"2007","journal-title":"N Engl J Med"},{"key":"37","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1016\/S0140-6736(08)61039-9","article-title":"Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial","volume":"37","author":"Kay","year":"2008","journal-title":"Lancet"},{"key":"38","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1056\/NEJMoa1109653","article-title":"Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer","volume":"36","author":"Yardley","year":"2012","journal-title":"N Engl J Med"},{"key":"39","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1016\/S0140-6736(15)00817-X","article-title":"Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study","volume":"38","author":"Sachs","year":"2016","journal-title":"Lancet"},{"key":"40","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.4161\/cc.8.12.8606","article-title":"Rapamycin decelerates cellular senescence","volume":"8","author":"Blagosklonny","year":"2009","journal-title":"Cell Cycle"},{"key":"41","doi-asserted-by":"publisher","first-page":"30210","DOI":"10.18632\/oncotarget.25788","article-title":"Does rapamycin slow down time?","volume":"9","author":"Blagosklonny","year":"2018","journal-title":"Oncotarget"},{"key":"42","doi-asserted-by":"publisher","first-page":"44876","DOI":"10.18632\/oncotarget.10381","article-title":"Rapamycin in aging and disease: maximizing efficacy while minimizing side effects","volume":"7","author":"Kaeberlein","year":"2016","journal-title":"Oncotarget"},{"key":"43","doi-asserted-by":"publisher","first-page":"8048","DOI":"10.18632\/aging.102355","article-title":"Rapamycin for longevity: opinion article","volume":"1","author":"Blagosklonny","year":"2019","journal-title":"Aging (Albany NY)"},{"key":"44","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1126\/science.1253462","article-title":"Spatial and temporal diversity in genomic instability processes defines lung cancer evolution","volume":"34","author":"Horswell","year":"2014","journal-title":"Science"},{"key":"45","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1158\/1940-6207.CAPR-10-0375","article-title":"Rapamycin is a potent inhibitor of skin tumor promotion by 12-O-tetradecanoylphorbol-13-acetate","volume":"4","author":"DiGiovanni","year":"2011","journal-title":"Cancer Prev Res (Phila)"},{"key":"46","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1093\/carcin\/bgw086","article-title":"mTOR inhibition prevents rapid-onset of carcinogen-induced malignancies in a novel inducible HPV-16 E6\/E7 mouse model","volume":"3","author":"Gutkind","year":"2016","journal-title":"Carcinogenesis"},{"key":"47","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1158\/1055-9965.EPI-07-0045","article-title":"The mammalian target of rapamycin pathway as a potential target for cancer chemoprevention","volume":"1","author":"Crowell","year":"2007","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"48","doi-asserted-by":"publisher","first-page":"109095","DOI":"10.1016\/j.clim.2022.109095","article-title":"Immunologic and dose dependent effects of rapamycin and its evolving role in chemoprevention","volume":"24","author":"Peoples","year":"2022","journal-title":"Clin Immunol"},{"key":"49","doi-asserted-by":"publisher","first-page":"1520","DOI":"10.4161\/cbt.7.10.6663","article-title":"Prevention of cancer by inhibiting aging","volume":"7","author":"Blagosklonny","year":"2008","journal-title":"Cancer Biol Ther"},{"key":"50","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.4161\/cc.5.18.3288","article-title":"Aging and immortality: quasi-programmed senescence and its pharmacologic inhibition","volume":"5","author":"Blagosklonny","year":"2006","journal-title":"Cell Cycle"},{"key":"51","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1111\/j.1476-5381.2008.00102.x","article-title":"Oral rapamycin attenuates inflammation and enhances stability of atherosclerotic plaques in rabbits independent of serum lipid levels","volume":"15","author":"Zhang","year":"2009","journal-title":"Br J Pharmacol"},{"key":"52","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.atherosclerosis.2007.09.019","article-title":"Prevention of atherosclerosis by the mTOR inhibitor everolimus in LDLR\u2212\/\u2212 mice despite severe hypercholesterolemia","volume":"19","author":"Thiery","year":"2008","journal-title":"Atherosclerosis"},{"key":"53","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1093\/ckj\/sfy041","article-title":"Effect of sirolimus on carotid atherosclerosis in kidney transplant recipients: data derived from a prospective randomized controlled trial","volume":"1","author":"de Andrade","year":"2018","journal-title":"Clin Kidney J"},{"key":"54","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1016\/j.cmet.2012.04.007","article-title":"TOR signaling and rapamycin influence longevity by regulating SKN-1\/Nrf and DAF-16\/FoxO","volume":"1","author":"Blackwell","year":"2012","journal-title":"Cell Metab"},{"key":"55","doi-asserted-by":"publisher","first-page":"dev177840","DOI":"10.1242\/dev.177840","article-title":"Deficient autophagy in epithelial stem cells drives aging in the freshwater cnidarian Hydra","volume":"14","author":"Galliot","year":"2020","journal-title":"Development"},{"key":"56","doi-asserted-by":"publisher","first-page":"eabo5482","DOI":"10.1126\/sciadv.abo5482","article-title":"Rapamycin treatment during development extends life span and health span of male mice and Daphnia magna","volume":"8","author":"Gladyshev","year":"2022","journal-title":"Sci Adv"},{"key":"57","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1101\/gad.1381406","article-title":"Extension of chronological life span in yeast by decreased TOR pathway signaling","volume":"2","author":"Fields","year":"2006","journal-title":"Genes Dev"},{"key":"58","doi-asserted-by":"publisher","first-page":"e55299","DOI":"10.15252\/embr.202255299","article-title":"Transient rapamycin treatment during developmental stage extends lifespan in Mus musculus and Drosophila melanogaster","volume":"2","author":"Tiberi","year":"2022","journal-title":"EMBO Rep"},{"key":"59","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1038\/s43587-022-00278-w","article-title":"Long-lasting geroprotection from brief rapamycin treatment in early adulthood by persistently increased intestinal autophagy","volume":"2","author":"Partridge","year":"2022","journal-title":"Nat Aging"},{"key":"60","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1080\/15384101.2022.2054636","article-title":"Cell senescence, rapamycin and hyperfunction theory of aging","volume":"2","author":"Blagosklonny","year":"2022","journal-title":"Cell Cycle"},{"key":"61","doi-asserted-by":"publisher","first-page":"407","DOI":"10.18632\/aging.100318","article-title":"Reversing the aging stromal phenotype prevents carcinoma initiation","volume":"3","author":"Spandau","year":"2011","journal-title":"Aging (Albany NY)"},{"key":"62","doi-asserted-by":"publisher","first-page":"3390","DOI":"10.18632\/aging.101128","article-title":"Aging promotes neoplastic disease through effects on the tissue microenvironment","volume":"8","author":"Laconi","year":"2016","journal-title":"Aging (Albany NY)"},{"key":"63","doi-asserted-by":"publisher","first-page":"735","DOI":"10.18632\/aging.100209","article-title":"Epithelial-mesenchymal transition and senescence: two cancer-related processes are crossing paths","volume":"2","author":"Peeper","year":"2010","journal-title":"Aging (Albany NY)"},{"key":"64","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1038\/ncb3195","article-title":"MTOR regulates the pro-tumorigenic senescence-associated secretory phenotype by promoting IL1A translation","volume":"1","author":"Li","year":"2015","journal-title":"Nat Cell Biol"},{"key":"65","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1016\/j.ajpath.2012.03.017","article-title":"Caveolin-1 and accelerated host aging in the breast tumor microenvironment: chemoprevention with rapamycin, an mTOR inhibitor and anti-aging drug","volume":"18","author":"Pestell","year":"2012","journal-title":"Am J Pathol"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.28410","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,14]],"date-time":"2023-04-14T08:30:39Z","timestamp":1681461039000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.28410"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,14]]},"references-count":65,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,4,14]]}},"alternative-id":["28410"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.28410","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,14]]}}}